UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of oncology, 2022-11, Vol.33 (11), p.1168-1178

2022

Volltextzugriff (PDF)

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Annals of oncology, 2023-01, Vol.34 (1), p.48-60

2023

Volltextzugriff (PDF)

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Annals of oncology, 2018-08, Vol.29 (8), p.1727-1740

2018

Volltextzugriff (PDF)

Integrated palliative care in Europe: a qualitative systematic literature review of empirically-tested models in cancer and chronic disease

BMC palliative care, 2016-07, Vol.15 (1), p.56, Article 56

2016

Volltextzugriff (PDF)

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Annals of oncology, 2019-10, Vol.30 (10), p.1670-1670

2019

Volltextzugriff (PDF)

Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors

Annals of oncology, 2019-07, Vol.30, p.iv125-iv125

2019

Volltextzugriff (PDF)

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

ESMO open, 2022-12, Vol.7 (6), p.100639, Article 100639

2022

Volltextzugriff (PDF)

Adapting a prescreening program to match molecular alterations in over 5,000 patients’ tumors with targeted agents and immunotherapies in early clinical trials over the last 8 years

Annals of oncology, 2018-09, Vol.29, p.vi23-vi23

2018

Volltextzugriff (PDF)

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)

ESMO open, 2024-04, Vol.9 (4), p.102254-102254, Article 102254

2024

Volltextzugriff (PDF)

A child's admission to hospital : a qualitative study examining the experiences of parents

Intensive care medicine, 2005-09, Vol.31 (9), p.1248-1254

2005

Volltextzugriff (PDF)

Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability

Annals of oncology, 2018-10, Vol.29, p.viii653-viii653

2018

Volltextzugriff (PDF)

Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)

Annals of oncology, 2018-10, Vol.29, p.viii45-viii45

2018

Volltextzugriff (PDF)

The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii547-viii547

2018

Volltextzugriff (PDF)

Aprendiendo sobre Cuidados Paliativos en África

Medicina paliativa, 2018-07, Vol.25 (3), p.119-120

2018

Volltextzugriff (PDF)

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

ESMO open, 2022-10, Vol.7 (5), p.100562-100562, Article 100562

2022

Volltextzugriff (PDF)

Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?

Annals of oncology, 2018-10, Vol.29, p.viii35-viii35

2018

Volltextzugriff (PDF)

Vall d’Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)

Annals of oncology, 2018-10, Vol.29, p.viii28-viii28

2018

Volltextzugriff (PDF)

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

ESMO open, 2021-06, Vol.6 (3), p.100131-100131, Article 100131

2021

Volltextzugriff (PDF)

Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors

Annals of oncology, 2018-10, Vol.29, p.viii123-viii123

2018

Volltextzugriff (PDF)

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

ESMO open, 2022-08, Vol.7 (4), p.100530-100530, Article 100530

2022

Volltextzugriff (PDF)

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

ESMO open, 2024-08, Vol.9 (8), p.103643, Article 103643

2024

Volltextzugriff (PDF)

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-08, Vol.383 (9), p.813-824

2020

Volltextzugriff (PDF)

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

ESMO open, 2021-12, Vol.6 (6), p.100281-100281, Article 100281

2021

Volltextzugriff (PDF)

Caring for patients with cancer in the COVID-19 era

Nature medicine, 2020-05, Vol.26 (5), p.665-671

2020

Volltextzugriff (PDF)

1 – 25 von 519

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(447)
Mit Volltextzugriff
(457)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(148)
Humans
(141)
Life Sciences & Biomedicine
(128)
Male
(83)
Child
(82)
Female
(81)
Adolescent
(71)
Biological And Medical Sciences
(65)
Psychiatry
(64)
Medical Sciences
(62)
Psychology. Psychoanalysis. Psychiatry
(48)
Psychopathology. Psychiatry
(42)
Children
(41)
Social Sciences
(35)
Psychology
(34)
Pediatrics
(33)
Psychology, Developmental
(30)
Adult
(26)
Adolescents
(24)
Oncology
(23)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(17)
... seit 30 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Integrated palliative care in Europe: a qualitative systematic literature review of empirically-tested models in cancer and chronic disease

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

Adapting a prescreening program to match molecular alterations in over 5,000 patients’ tumors with targeted agents and immunotherapies in early clinical trials over the last 8 years

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)

A child's admission to hospital : a qualitative study examining the experiences of parents

Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability

Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)

The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors

Aprendiendo sobre Cuidados Paliativos en África

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?

Vall d’Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

Caring for patients with cancer in the COVID-19 era

Suchergebnisse filtern